GlaxoSmithKline plc (LON:GSK) had its price target cut by Berenberg Bank from GBX 1,835 ($24.21) to GBX 1,760 ($23.23) in a research note issued to investors on Thursday morning. They currently have a buy rating on the stock.

Several other research firms have also recently commented on GSK. UBS AG set a GBX 1,600 ($21.11) price target on shares of GlaxoSmithKline plc and gave the company a neutral rating in a report on Wednesday, July 26th. HSBC Holdings plc set a GBX 1,925 ($25.40) price target on shares of GlaxoSmithKline plc and gave the company a buy rating in a report on Thursday, October 26th. Deutsche Bank AG set a GBX 1,610 ($21.25) price target on shares of GlaxoSmithKline plc and gave the company a neutral rating in a report on Friday, October 27th. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($25.07) price target on shares of GlaxoSmithKline plc and gave the company a buy rating in a report on Tuesday, August 8th. Finally, Jefferies Group LLC restated a buy rating and set a GBX 1,900 ($25.07) price target on shares of GlaxoSmithKline plc in a report on Thursday, July 13th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have assigned a buy rating to the stock. GlaxoSmithKline plc currently has an average rating of Hold and a consensus target price of GBX 1,619.75 ($21.37).

GlaxoSmithKline plc (LON GSK) traded up GBX 9.50 ($0.13) during trading on Thursday, hitting GBX 1,361 ($17.96). 7,047,222 shares of the stock traded hands.

GlaxoSmithKline plc (LON:GSK) last posted its quarterly earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) EPS for the quarter, beating the consensus estimate of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). GlaxoSmithKline plc had a negative net margin of 1.17% and a negative return on equity of 57.19%. The business had revenue of GBX 784.30 billion for the quarter.

COPYRIGHT VIOLATION NOTICE: This report was first reported by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.watchlistnews.com/glaxosmithkline-plc-gsk-price-target-cut-to-gbx-1760-by-analysts-at-berenberg-bank/1679209.html.

The business also recently disclosed a dividend, which will be paid on Thursday, January 11th. Stockholders of record on Thursday, November 9th will be given a dividend of GBX 19 ($0.25) per share. This represents a dividend yield of 1.41%. The ex-dividend date is Thursday, November 9th.

In related news, insider Urs Rohner acquired 473 shares of the business’s stock in a transaction dated Wednesday, October 25th. The stock was acquired at an average price of GBX 1,518 ($20.03) per share, with a total value of £7,180.14 ($9,474.98). Also, insider Simon Dingemans acquired 1,076 shares of the business’s stock in a transaction dated Thursday, October 12th. The shares were bought at an average cost of GBX 1,527 ($20.15) per share, with a total value of £16,430.52 ($21,681.87). Insiders have bought 1,574 shares of company stock valued at $2,398,888 in the last ninety days.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.